Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 16 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingNCT06364904Phase 3
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
• CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
• A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06363825Phase 2
• Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial CancerNot yet recruitingNCT06363708Not applicable
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)RecruitingNCT06362252Phase 1/2
• A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC PatientsRecruitingNCT06361927Phase 2
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
• PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence PatientsRecruitingNCT06359275Phase 2
• Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerRecruitingNCT06357598Phase 4
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingNCT06357533Phase 3
• A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
• Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2
• DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUCRecruitingNCT06354231Phase 2
• Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old AgeRecruitingNCT06354218Phase 2
• Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerRecruitingNCT06353906Phase 2
• TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.RecruitingNCT06353360Phase 2
• SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid TumorRecruitingNCT06350006Phase 1
• Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric CancerNot yet recruitingNCT06349967Phase 2
• Adebrelimab and Chemoradiotherapy in High-risk LANPCRecruitingNCT06349889Phase 2
• Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsRecruitingNCT06349837Phase 1
• Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingNCT06346197Phase 3
• Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Phase 2
• NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingNCT06342037Phase 2
• Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNomaRecruitingNCT06341764Phase 2
• To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06341660Phase 2
• Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALMRecruitingNCT06341595Phase 2
• A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06341335Phase 3
• SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast CancerRecruitingNCT06340230Phase 2
• Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Phase 2
• Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06339424Phase 2
• A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.Not yet recruitingNCT06339216Phase 2
• Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingNCT06336902Phase 1
• A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingNCT06335355Phase 2/3
• PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon CancerNot yet recruitingNCT06335147Not applicable
• Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureRecruitingNCT06334757Phase 2
• Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingNCT06333314Phase 2
• Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
• tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseRecruitingNCT06332274Phase 3
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
• A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung CancerRecruitingNCT06331650Phase 2
• Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and ResectionRecruitingNCT06331455Phase 2
• Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy FailureNot yet recruitingNCT06327698Phase 2
• SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal CarcinomaRecruitingNCT06323239Phase 2
• ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingNCT06321081Phase 2
• Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06320405Phase 1/2
• Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaRecruitingNCT06319196Phase 2
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerRecruitingNCT06318897Phase 2
• Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell LymphomaRecruitingNCT06314334Phase 2
• Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)RecruitingNCT06313190Phase 2
• A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal CancerRecruitingNCT06312982Phase 2/3
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
• Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialNot yet recruitingNCT06310473Phase 2
• Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingNCT06308939Phase 2
• A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid TumorsRecruitingNCT06307925Phase 1
• A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.Not yet recruitingNCT06306560Phase 2
• Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Not yet recruitingNCT06304818Phase 1/2
• Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular EndoscopyNot yet recruitingNCT06304597Phase 1
• Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With CamrelizumabNot yet recruitingNCT06304545Phase 2
• Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06303583Phase 1/2
• Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2
• Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid TumorsRecruitingNCT06302062Phase 1
• Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal TumorsRecruitingNCT06301828Phase 2
• Everolimus Combined With PD-1 in Advanced Colorectal Cancer PatientsNot yet recruitingNCT06301386Phase 2
• Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNot yet recruitingNCT06299371Phase 2
• Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAICRecruitingNCT06296563Phase 2
• Serplulimab Combined With CCRT for LS-SCLC.RecruitingNCT06295926Phase 2
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2
• A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCRecruitingNCT06294548Phase 1/2
• Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06293651Phase 1/2
• A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO StudyRecruitingNCT06290505Phase 2
• Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical CancerRecruitingNCT06289751Phase 2
• Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical CancerRecruitingNCT06289062Phase 2
• Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACCRecruitingNCT06288373Phase 2/3
• Neoadjuvant Immunochemotherapy in PD-L1-negative LACCRecruitingNCT06288360Phase 2
• Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaRecruitingNCT06288191Phase 2
• Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
• A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283303Phase 1
• A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283134Phase 1
• A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric CancerNot yet recruitingNCT06283121Phase 2
• Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal CancerRecruitingNCT06282445Phase 2
• CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal CancerRecruitingNCT06281405Phase 2
• Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract CancerRecruitingNCT06280508Phase 2
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC PatientsRecruitingNCT06280495Phase 2/3
• A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingNCT06280105Phase 2
• SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingNCT06278857Phase 2
• The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell CarcinomaRecruitingNCT06277791Phase 2
• Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
• Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal CarcinomaRecruitingNCT06277050Phase 3
• A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06276933Phase 4
• Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV InfectionNot yet recruitingNCT06276504Phase 2/3
• Repositioning Immunotherapy in VetArans With Lung CancerRecruitingNCT06275360Phase 2
• Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive ExpressionRecruitingNCT06269211Phase 2
• The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal AdenocarcinomaRecruitingNCT06266832Phase 2
• Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2
• GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsRecruitingNCT06265025Phase 1/2
• Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingNCT06263153Phase 2
• Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before SurgeryRecruitingNCT06262581Phase 2

← Immune Checkpoint Inhibitors overview